Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;52(6):898-901.
doi: 10.1038/bmt.2017.7. Epub 2017 Feb 20.

Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation

J Zou  1 , R Romee  2 , M Slade  2 , D Phelan  3 , J Keller  2 , T Mohanakumar  4 , B J Grossman  1   5
Affiliations

Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation

J Zou et al. Bone Marrow Transplant. 2017 Jun.
No abstract available

PubMed Disclaimer

Figures

Fig. 1A.
Fig. 1A.
Overall Survival by DSA status. The solid line represents no DSAs, and the dashed line represents patients without DSAs (no HLA-antibody or no donor specific anti-HLA antibody).
Fig. 1B.
Fig. 1B.
Treatment-Related Mortality.
Fig. 1C.
Fig. 1C.
Survival by C1q Status. The solid line represents C1q negative, and the dashed line represents C1q positive.
See this image and copyright information in PMC

References

    1. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008/05/21 ed. 2008;14(6):641–50. - PMC - PubMed
    1. Ciurea SO, Zhang M-J, Bacigalupo A a, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):blood – 2015–04 – 639831. - PMC - PubMed
    1. Bashey A, Zhang X, Sizemore C a., Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31(10):1310–6. - PubMed
    1. Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, et al. Comparison of outcomes following peripheral blood haploidentical vs. matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review. Biol Blood Marrow Transplant. 2016. May; - PubMed
    1. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. United States; 2009. October;88(8):1019–24. - PMC - PubMed

Publication types